News | Radiation Therapy | April 07, 2022

ASTRO released a statement in response to the proposed rule issued April 6 by CMS that will delay the Radiation Oncology (RO) Model, which was scheduled to go into effect in January 1, 2023

The American Society for Radiation Oncology (ASTRO) issued the following statement from ASTRO Board of Directors Chair Laura A. Dawson, MD, FASTRO, in response to the Centers for Medicare and Medicaid Services' (CMS) decision to delay the start of the Radiation Oncology Alternative Payment Model (RO-APM)

Getty Images


April 7, 2022 — The American Society for Radiation Oncology (ASTRO) issued the following statement from ASTRO Board of Directors Chair Laura A. Dawson, MD, FASTRO, in response to the Centers for Medicare and Medicaid Services' (CMS) decision to delay the start of the Radiation Oncology Alternative Payment Model (RO-APM):

"The Centers for Medicare and Medicaid Services today delayed the Radiation Oncology Alternative Payment Model start date from January 1, 2023, to a date to be determined through future rulemaking.  ASTRO remains hopeful that during this process, CMS also makes the adjustments recommended by Congress and the broad coalition of stakeholders within the radiation oncology community as we remain concerned that the model in its current form is too punitive for clinics. We remain committed to value-based care in radiation oncology. We believe that the modifications proposed by ASTRO and the radiation oncology community will ensure successful participation among physicians and facilities and produce significant savings for the Medicare program.  We continue to believe that episodic payments for radiation therapy services have great potential to improve quality and equity while reducing cancer care costs, and we will continue to advocate for proposals that achieve these goals.”

For more information: www.astro.org

Related CMS Content:

ASTRO Urges Congress to Pass Legislation Delaying RO Model and Protecting Medicare Beneficiaries' Access to Care

ASTRO Deeply Concerned and Disappointed Over CMS 2022 Final Rules

Senators and representatives unite to call on CMS to protect patient access to high-quality radiation treatments

 

Related Content

News | Proton Therapy

July 1, 2022 — IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology ...

Time July 01, 2022
arrow
News | Prostate Cancer

July 1, 2022 — Insightec, a global healthcare company dedicated to using acoustic energy to transform patient care ...

Time July 01, 2022
arrow
News | Magnetic Resonance Imaging (MRI)

June 30, 2022 — When a patient with head and neck cancer has surgery to remove it, they often need reconstructive ...

Time June 30, 2022
arrow
News | Proton Therapy

June 29, 2022 — ProtOnART builds upon the partners’ long-standing research efforts and shared ambition that an online ...

Time June 29, 2022
arrow
News | Lung Imaging

June 29, 2022 — Building on Penn Medicine’s years of research and use of imaging technology that illuminates tumor ...

Time June 29, 2022
arrow
News | Proton Therapy

June 27, 2022 — Varian, a Siemens Healthineers company, announced that the U.S. Food and Drug Administration (FDA) ...

Time June 28, 2022
arrow
News | Radiation Oncology

June 27, 2022 — Neutron Therapeutics, Inc (NT) and the University Hospital of Brussels (H.U.B) today announced that they ...

Time June 28, 2022
arrow
News | Radiation Therapy

June 24, 2022 — Recently, a collaborated research team led by Prof. LI Hai and Hongzhi Wang from Hefei Institutes of ...

Time June 24, 2022
arrow
News | Radiation Therapy

June 23, 2022 — RaySearch Laboratories AB announced the release of the latest version of RayCare*, the next generation ...

Time June 23, 2022
arrow
News | Radiation Therapy

June 17, 2022 — Accuray Incorporated and Limbus AI Inc. announced they are partnering to augment Accuray adaptive ...

Time June 17, 2022
arrow
Subscribe Now